Diabetic amyotrophy

What it is

Diabetic amyotrophy is a rare but serious complication of diabetes that causes sudden, severe pain and progressive muscle weakness in the hips, thighs, and buttocks, affecting an estimated 1% of people with diabetes and most commonly striking those with type 2 diabetes in their 50s and 60s. Also known as diabetic lumbosacral radiculoplexus neuropathy (DLRPN) or Bruns-Garland syndrome, it is a distinct condition from the far more common symmetric peripheral neuropathy of diabetes — the gradual numbness and tingling that starts in the feet.

Unlike peripheral neuropathy, diabetic amyotrophy typically begins on one side of the body and involves an inflammatory process affecting the nerve's blood supply, not just metabolic nerve damage from chronic high blood sugar. It is under-recognized in Canadian clinical practice partly because its presentation — sudden unilateral hip pain, night pain, and rapid muscle wasting — mimics lumbar disc disease or hip pathology, leading to delays in diagnosis.

The condition most often appears in people who are already managing type 2 diabetes, and it sometimes coincides with a period of significant weight loss, whether intentional or illness-related. Diabetes Canada's clinical practice guidelines recognize diabetic radiculoplexus neuropathies as a distinct subtype of diabetic neuropathy requiring targeted assessment.

Comparison: Diabetic amyotrophy vs. peripheral diabetic neuropathy

Feature	Diabetic amyotrophy	Peripheral diabetic neuropathy
Onset	Sudden, over days to weeks	Gradual, over months to years
Pain character	Severe, aching/burning; often nocturnal	Burning, tingling, or numbness
Distribution	Proximal (hip, thigh, buttock); often unilateral	Distal, symmetric ("stocking-glove")
Muscle weakness	Prominent; quadriceps wasting common	Mild or absent in early stages
Primary mechanism	Inflammatory microvasculitis	Metabolic nerve damage
Typical diabetes type	Type 2, age 50s–60s	Both types; duration-dependent
Spontaneous recovery	Common but slow (6–24 months)	Rarely reverses

Causes and mechanism

The exact mechanism is not fully understood, but the leading explanation is inflammatory microvasculitis — damage to the small epineurial blood vessels that supply the lumbosacral nerve roots and plexus. When these vessels become inflamed, the nerve tissue downstream becomes ischemic and begins to fail.

Several overlapping processes appear to contribute:

1. Microvasculitis: Inflammatory cell infiltration of the vessels supplying the lumbosacral plexus, confirmed on nerve biopsy in a subset of patients, causes focal nerve ischemia and axonal loss.
2. Immune-mediated injury: Tissue analysis from affected nerves shows T-cell and macrophage infiltration, pointing to an autoimmune component that distinguishes this condition from purely metabolic neuropathy.
3. Chronic hyperglycemia: Sustained elevated blood glucose promotes systemic inflammation and oxidative stress, increasing the vulnerability of the microvascular nerve supply over time.
4. Rapid glycemic improvement: Paradoxically, some cases appear to be triggered by a sudden, significant drop in blood sugar — possibly through abrupt changes in nerve blood flow. This means glycemic optimization should be gradual rather than abrupt in people at risk.

Symptoms and diagnosis

The condition typically unfolds in three phases:

Phase 1 — Pain onset: Sudden, severe aching or burning pain in one hip, thigh, or buttock. Pain is often worst at night and can be severe enough to prevent sleep. Unexplained weight loss frequently accompanies or precedes this phase.

Phase 2 — Weakness: Progressive wasting and weakness of the thigh muscles, particularly the quadriceps. Patients report difficulty rising from a chair, climbing stairs, or standing from a crouched position. The knee reflex is often absent or reduced on the affected side. In a significant proportion of patients, weakness eventually spreads to the opposite side.

Phase 3 — Recovery: Gradual, spontaneous improvement over 6 to 24 months in most patients, though recovery is often incomplete. Some residual weakness is common.

Diagnosis is clinical first, supported by investigations:

• Nerve conduction studies and EMG — identify lumbosacral plexus involvement and distinguish the condition from lumbar disc disease or myopathy
• MRI of the lumbosacral plexus — may show nerve thickening or gadolinium enhancement indicating active inflammation
• Blood tests — fasting glucose, HbA1c, and inflammatory markers confirm the diabetic context and rule out other causes
• Nerve biopsy — reserved for diagnostically uncertain cases; confirms microvasculitis when present

In Canada, nerve conduction studies and EMG are available through neurology referrals at most regional hospitals and academic centres. LifeLabs and Dynacare can process the blood work component; the specialized neurophysiology testing requires a specialist referral.

Treatment options

There is no specific cure. Treatment focuses on pain control, glycemic optimization, and functional rehabilitation — and most patients do improve over time.

• Glycemic control: Optimizing blood sugar management is the most important long-term step. It reduces further nerve damage and supports the recovery environment, though changes should be gradual to avoid triggering further ischemic events.
• Neuropathic pain management: First-line agents include tricyclic antidepressants (amitriptyline), anticonvulsants (gabapentin, pregabalin), and SNRIs (duloxetine). All are available in Canada and covered under most provincial formularies for neuropathic pain indications. In severe or refractory cases, short courses of oral or intravenous corticosteroids or intravenous immunoglobulin (IVIG) have been used, though evidence from randomized trials remains limited.
• Physical therapy: Essential throughout recovery. A structured physiotherapy program helps preserve quadriceps function, prevent falls, and rebuild strength as the inflammatory phase resolves.
• Nutritional support: Adequate protein and caloric intake matters, particularly when significant weight loss has occurred around the time of onset.
• Monitoring: Most patients stabilize and begin improving once the acute inflammatory phase passes. Follow-up with neurology and endocrinology every 3 to 6 months is reasonable during the active phase.

When to see a clinician in Canada

See a physician promptly — ideally within days — if you have diabetes and experience any of the following:

• Sudden, severe pain in the hip, thigh, or buttock that is unlike any previous pain
• Progressive weakness in the thigh or new difficulty standing from a seated position
• Unexplained weight loss occurring alongside or just before the pain onset
• Loss or reduction of the knee reflex on one or both sides

Tell your clinician about your diabetes history alongside these specific symptoms. Without that context, the presentation is easily attributed to a lumbar disc problem or hip arthritis, and the appropriate neurological investigations may be delayed. A referral to neurology or a diabetes specialist (endocrinologist or internist) is the typical next step in most Canadian provinces. Telehealth platforms such as Maple can facilitate an initial assessment and triage to the right specialist if in-person access is delayed.

Limitations and open questions

Research is still emerging on several aspects of this condition. The evidence base for immunotherapy — corticosteroids and IVIG — comes largely from case series and small observational studies rather than randomized controlled trials, so the magnitude of benefit remains uncertain. A Cochrane review on immunotherapy for diabetic amyotrophy found insufficient high-quality evidence to make firm recommendations.

The precise trigger for why microvasculitis develops in some people with diabetes and not others is not known. The role of rapid glycemic improvement as a precipitant is based on case reports and mechanistic reasoning rather than prospective data. Health Canada has not issued specific guidance on the use of IVIG for this indication outside of broader neuropathy frameworks, and provincial coverage for IVIG in this context varies. The optimal duration of physical therapy and whether early immunotherapy changes long-term functional outcomes are both areas where further research is needed.